nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—PTGS2—amyotrophic lateral sclerosis	0.682	1	CbGaD
Meloxicam—Rheumatoid arthritis—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0438	CcSEcCtD
Meloxicam—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.0109	0.0387	CcSEcCtD
Meloxicam—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0371	CcSEcCtD
Meloxicam—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00643	0.0228	CcSEcCtD
Meloxicam—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00538	0.0191	CcSEcCtD
Meloxicam—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00519	0.0184	CcSEcCtD
Meloxicam—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00455	0.0161	CcSEcCtD
Meloxicam—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00395	0.014	CcSEcCtD
Meloxicam—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00393	0.0139	CcSEcCtD
Meloxicam—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00365	0.0129	CcSEcCtD
Meloxicam—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00311	0.011	CcSEcCtD
Meloxicam—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00309	0.0109	CcSEcCtD
Meloxicam—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0107	CcSEcCtD
Meloxicam—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0106	CcSEcCtD
Meloxicam—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0102	CcSEcCtD
Meloxicam—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00288	0.0102	CcSEcCtD
Meloxicam—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00997	CcSEcCtD
Meloxicam—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00993	CcSEcCtD
Meloxicam—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00989	CcSEcCtD
Meloxicam—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00985	CcSEcCtD
Meloxicam—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00961	CcSEcCtD
Meloxicam—Lornoxicam—PTGS2—amyotrophic lateral sclerosis	0.0027	0.409	CrCbGaD
Meloxicam—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00946	CcSEcCtD
Meloxicam—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00928	CcSEcCtD
Meloxicam—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00914	CcSEcCtD
Meloxicam—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0091	CcSEcCtD
Meloxicam—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00894	CcSEcCtD
Meloxicam—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00887	CcSEcCtD
Meloxicam—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00865	CcSEcCtD
Meloxicam—Tenoxicam—PTGS2—amyotrophic lateral sclerosis	0.0024	0.365	CrCbGaD
Meloxicam—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0024	0.0085	CcSEcCtD
Meloxicam—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00847	CcSEcCtD
Meloxicam—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0083	CcSEcCtD
Meloxicam—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0083	CcSEcCtD
Meloxicam—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00814	CcSEcCtD
Meloxicam—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00809	CcSEcCtD
Meloxicam—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00799	CcSEcCtD
Meloxicam—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00796	CcSEcCtD
Meloxicam—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00789	CcSEcCtD
Meloxicam—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00767	CcSEcCtD
Meloxicam—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00758	CcSEcCtD
Meloxicam—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00756	CcSEcCtD
Meloxicam—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00751	CcSEcCtD
Meloxicam—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0074	CcSEcCtD
Meloxicam—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0074	CcSEcCtD
Meloxicam—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0073	CcSEcCtD
Meloxicam—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00726	CcSEcCtD
Meloxicam—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00722	CcSEcCtD
Meloxicam—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00722	CcSEcCtD
Meloxicam—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00203	0.0072	CcSEcCtD
Meloxicam—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00201	0.0071	CcSEcCtD
Meloxicam—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00706	CcSEcCtD
Meloxicam—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00198	0.007	CcSEcCtD
Meloxicam—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00695	CcSEcCtD
Meloxicam—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00691	CcSEcCtD
Meloxicam—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00668	CcSEcCtD
Meloxicam—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00666	CcSEcCtD
Meloxicam—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00665	CcSEcCtD
Meloxicam—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00665	CcSEcCtD
Meloxicam—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0066	CcSEcCtD
Meloxicam—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00656	CcSEcCtD
Meloxicam—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00655	CcSEcCtD
Meloxicam—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00653	CcSEcCtD
Meloxicam—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00652	CcSEcCtD
Meloxicam—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00628	CcSEcCtD
Meloxicam—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00621	CcSEcCtD
Meloxicam—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00617	CcSEcCtD
Meloxicam—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00603	CcSEcCtD
Meloxicam—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.006	CcSEcCtD
Meloxicam—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00599	CcSEcCtD
Meloxicam—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00594	CcSEcCtD
Meloxicam—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00587	CcSEcCtD
Meloxicam—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00582	CcSEcCtD
Meloxicam—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00579	CcSEcCtD
Meloxicam—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0057	CcSEcCtD
Meloxicam—Tension—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00568	CcSEcCtD
Meloxicam—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00567	CcSEcCtD
Meloxicam—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00562	CcSEcCtD
Meloxicam—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0056	CcSEcCtD
Meloxicam—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00556	CcSEcCtD
Meloxicam—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00542	CcSEcCtD
Meloxicam—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00537	CcSEcCtD
Meloxicam—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00535	CcSEcCtD
Meloxicam—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00529	CcSEcCtD
Meloxicam—Piroxicam—PTGS2—amyotrophic lateral sclerosis	0.00148	0.225	CrCbGaD
Meloxicam—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00522	CcSEcCtD
Meloxicam—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0052	CcSEcCtD
Meloxicam—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00519	CcSEcCtD
Meloxicam—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00518	CcSEcCtD
Meloxicam—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00511	CcSEcCtD
Meloxicam—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00509	CcSEcCtD
Meloxicam—Cough—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00505	CcSEcCtD
Meloxicam—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00501	CcSEcCtD
Meloxicam—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00141	0.005	CcSEcCtD
Meloxicam—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00493	CcSEcCtD
Meloxicam—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00493	CcSEcCtD
Meloxicam—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00491	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00489	CcSEcCtD
Meloxicam—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00487	CcSEcCtD
Meloxicam—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00482	CcSEcCtD
Meloxicam—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00476	CcSEcCtD
Meloxicam—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00472	CcSEcCtD
Meloxicam—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00472	CcSEcCtD
Meloxicam—Infection—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00469	CcSEcCtD
Meloxicam—Shock—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00465	CcSEcCtD
Meloxicam—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00463	CcSEcCtD
Meloxicam—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00462	CcSEcCtD
Meloxicam—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00461	CcSEcCtD
Meloxicam—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00459	CcSEcCtD
Meloxicam—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00457	CcSEcCtD
Meloxicam—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00441	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0043	CcSEcCtD
Meloxicam—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00427	CcSEcCtD
Meloxicam—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00424	CcSEcCtD
Meloxicam—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00421	CcSEcCtD
Meloxicam—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0042	CcSEcCtD
Meloxicam—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00416	CcSEcCtD
Meloxicam—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00411	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00408	CcSEcCtD
Meloxicam—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00407	CcSEcCtD
Meloxicam—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00404	CcSEcCtD
Meloxicam—Pain—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00404	CcSEcCtD
Meloxicam—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00389	CcSEcCtD
Meloxicam—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00386	CcSEcCtD
Meloxicam—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00375	CcSEcCtD
Meloxicam—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00373	CcSEcCtD
Meloxicam—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00373	CcSEcCtD
Meloxicam—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00348	CcSEcCtD
Meloxicam—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000957	0.00339	CcSEcCtD
Meloxicam—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000944	0.00334	CcSEcCtD
Meloxicam—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000913	0.00323	CcSEcCtD
Meloxicam—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00312	CcSEcCtD
Meloxicam—PGD—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000874	0.0306	CbGpPWpGaD
Meloxicam—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000848	0.003	CcSEcCtD
Meloxicam—Rash—Riluzole—amyotrophic lateral sclerosis	0.000841	0.00298	CcSEcCtD
Meloxicam—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00084	0.00297	CcSEcCtD
Meloxicam—Headache—Riluzole—amyotrophic lateral sclerosis	0.000836	0.00296	CcSEcCtD
Meloxicam—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.000794	0.0278	CbGpPWpGaD
Meloxicam—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000793	0.00281	CcSEcCtD
Meloxicam—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.000646	0.0226	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000639	0.0224	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.000602	0.0211	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.000589	0.0206	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—TUBA4A—amyotrophic lateral sclerosis	0.000585	0.0205	CbGpPWpGaD
Meloxicam—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.000582	0.0204	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.000557	0.0195	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	0.000526	0.0184	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	0.000502	0.0176	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000493	0.0173	CbGpPWpGaD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000429	0.015	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000386	0.0135	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000367	0.0129	CbGpPWpGaD
Meloxicam—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	0.000366	0.0128	CbGpPWpGaD
Meloxicam—PTGS1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000352	0.0123	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.000348	0.0122	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000323	0.0113	CbGpPWpGaD
Meloxicam—PGD—Disease—TPK1—amyotrophic lateral sclerosis	0.000309	0.0108	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000292	0.0102	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.000288	0.0101	CbGpPWpGaD
Meloxicam—PTGS1—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	0.000286	0.01	CbGpPWpGaD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000283	0.00991	CbGpPWpGaD
Meloxicam—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00028	0.0098	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000259	0.00908	CbGpPWpGaD
Meloxicam—PGD—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000259	0.00907	CbGpPWpGaD
Meloxicam—PGD—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000259	0.00907	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000255	0.00891	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.000254	0.00891	CbGpPWpGaD
Meloxicam—PGD—Disease—VTA1—amyotrophic lateral sclerosis	0.000247	0.00866	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	0.000247	0.00866	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.000242	0.00849	CbGpPWpGaD
Meloxicam—PTGS1—Eicosanoid Synthesis—PTGS2—amyotrophic lateral sclerosis	0.000238	0.00832	CbGpPWpGaD
Meloxicam—PGD—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000237	0.0083	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000235	0.00823	CbGpPWpGaD
Meloxicam—PTGS1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000234	0.0082	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000234	0.00817	CbGpPWpGaD
Meloxicam—PGD—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00022	0.00771	CbGpPWpGaD
Meloxicam—PGD—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000207	0.00725	CbGpPWpGaD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.000205	0.00719	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.0002	0.007	CbGpPWpGaD
Meloxicam—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000199	0.00696	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000196	0.00687	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000193	0.00675	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000192	0.00671	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.000189	0.00663	CbGpPWpGaD
Meloxicam—PGD—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000187	0.00656	CbGpPWpGaD
Meloxicam—PGD—Metabolism—DAO—amyotrophic lateral sclerosis	0.000187	0.00656	CbGpPWpGaD
Meloxicam—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000186	0.00651	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000186	0.00651	CbGpPWpGaD
Meloxicam—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.000179	0.00627	CbGpPWpGaD
Meloxicam—PGD—Disease—PLB1—amyotrophic lateral sclerosis	0.00017	0.00594	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000167	0.00584	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000166	0.00582	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000163	0.00571	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000163	0.00571	CbGpPWpGaD
Meloxicam—ABCC4—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000156	0.00545	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000155	0.00543	CbGpPWpGaD
Meloxicam—ABCC4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000154	0.00537	CbGpPWpGaD
Meloxicam—CYP2C8—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000151	0.0053	CbGpPWpGaD
Meloxicam—PGD—Disease—VCP—amyotrophic lateral sclerosis	0.000151	0.00529	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000149	0.00523	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000148	0.00518	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000142	0.00497	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000139	0.00486	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000137	0.00479	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000134	0.00468	CbGpPWpGaD
Meloxicam—PTGS1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000132	0.00462	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000132	0.00462	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GSR—amyotrophic lateral sclerosis	0.000131	0.00459	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00013	0.00457	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00013	0.00454	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000124	0.00435	CbGpPWpGaD
Meloxicam—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000123	0.00431	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.00012	0.00421	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000119	0.00415	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000113	0.00395	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000112	0.00392	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000111	0.0039	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00011	0.00386	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000109	0.00381	CbGpPWpGaD
Meloxicam—PGD—Disease—CST3—amyotrophic lateral sclerosis	0.000108	0.0038	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000108	0.00377	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000108	0.00377	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000105	0.00369	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000104	0.00363	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000102	0.00358	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	0.000101	0.00355	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000101	0.00354	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	9.8e-05	0.00343	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	9.73e-05	0.00341	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	9.66e-05	0.00338	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	9.64e-05	0.00338	CbGpPWpGaD
Meloxicam—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.49e-05	0.00332	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.15e-05	0.0032	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.15e-05	0.0032	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.97e-05	0.00314	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.94e-05	0.00313	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	8.83e-05	0.00309	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	8.58e-05	0.003	CbGpPWpGaD
Meloxicam—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.53e-05	0.00299	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.43e-05	0.00295	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	8.4e-05	0.00294	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	8.3e-05	0.00291	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.15e-05	0.00285	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.91e-05	0.00277	CbGpPWpGaD
Meloxicam—PGD—Disease—CASP9—amyotrophic lateral sclerosis	7.89e-05	0.00276	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.85e-05	0.00275	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	7.35e-05	0.00257	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	7.3e-05	0.00255	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	7.27e-05	0.00254	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	7.27e-05	0.00254	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.1e-05	0.00249	CbGpPWpGaD
Meloxicam—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.94e-05	0.00243	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	6.89e-05	0.00241	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	6.88e-05	0.00241	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.86e-05	0.0024	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.78e-05	0.00237	CbGpPWpGaD
Meloxicam—PGD—Disease—ERBB4—amyotrophic lateral sclerosis	6.75e-05	0.00236	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.67e-05	0.00233	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.65e-05	0.00233	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.36e-05	0.00223	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.18e-05	0.00216	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.13e-05	0.00215	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.04e-05	0.00212	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—SOD1—amyotrophic lateral sclerosis	5.82e-05	0.00204	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.81e-05	0.00203	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.78e-05	0.00202	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.78e-05	0.00202	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.77e-05	0.00202	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.77e-05	0.00202	CbGpPWpGaD
Meloxicam—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	5.51e-05	0.00193	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.38e-05	0.00188	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.32e-05	0.00186	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	5.28e-05	0.00185	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	5.26e-05	0.00184	CbGpPWpGaD
Meloxicam—PGD—Disease—APOE—amyotrophic lateral sclerosis	5.22e-05	0.00183	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	5.22e-05	0.00183	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.99e-05	0.00175	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.92e-05	0.00172	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.91e-05	0.00172	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	4.9e-05	0.00171	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.7e-05	0.00165	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	4.7e-05	0.00164	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	4.7e-05	0.00164	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	4.63e-05	0.00162	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.61e-05	0.00162	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	4.5e-05	0.00157	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.38e-05	0.00153	CbGpPWpGaD
Meloxicam—PGD—Metabolism—APOE—amyotrophic lateral sclerosis	4.37e-05	0.00153	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.33e-05	0.00151	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	4.29e-05	0.0015	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	4.17e-05	0.00146	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	4.17e-05	0.00146	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.99e-05	0.0014	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.98e-05	0.00139	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.82e-05	0.00134	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.82e-05	0.00134	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	3.78e-05	0.00132	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	3.75e-05	0.00131	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.68e-05	0.00129	CbGpPWpGaD
Meloxicam—PGD—Disease—PTGS2—amyotrophic lateral sclerosis	3.58e-05	0.00125	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.56e-05	0.00125	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.55e-05	0.00124	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.5e-05	0.00122	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	3.39e-05	0.00119	CbGpPWpGaD
Meloxicam—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	3.37e-05	0.00118	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.35e-05	0.00117	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.33e-05	0.00117	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.29e-05	0.00115	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.25e-05	0.00114	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.24e-05	0.00114	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.16e-05	0.00111	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	3.14e-05	0.0011	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.06e-05	0.00107	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.02e-05	0.00106	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PTGS2—amyotrophic lateral sclerosis	3e-05	0.00105	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	2.92e-05	0.00102	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.83e-05	0.000989	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.76e-05	0.000967	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.75e-05	0.000964	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.66e-05	0.00093	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.57e-05	0.000901	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.52e-05	0.000882	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.52e-05	0.000882	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	2.42e-05	0.000845	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.4e-05	0.000839	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	2.37e-05	0.000831	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.32e-05	0.000811	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.31e-05	0.000807	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000765	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.16e-05	0.000757	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.14e-05	0.00075	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.14e-05	0.000748	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.09e-05	0.000733	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.01e-05	0.000705	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.95e-05	0.000683	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.93e-05	0.000676	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.89e-05	0.000661	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.82e-05	0.000638	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.78e-05	0.000623	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	0.000616	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	1.76e-05	0.000615	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TP53—amyotrophic lateral sclerosis	1.75e-05	0.000613	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.62e-05	0.000568	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.59e-05	0.000556	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.5e-05	0.000526	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.49e-05	0.000522	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.45e-05	0.000507	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.38e-05	0.000483	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.29e-05	0.000451	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.27e-05	0.000446	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.23e-05	0.000429	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.22e-05	0.000427	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.18e-05	0.000414	CbGpPWpGaD
Meloxicam—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.16e-05	0.000407	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.05e-05	0.000367	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.05e-05	0.000366	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.92e-06	0.000347	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	9.74e-06	0.000341	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.63e-06	0.000337	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.53e-06	0.000299	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.4e-06	0.000294	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	7.92e-06	0.000277	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.84e-06	0.000274	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	6.45e-06	0.000226	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.62e-06	0.000197	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.43e-06	0.00019	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.17e-06	0.000181	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.42e-06	0.000155	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.25e-06	0.000149	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.91e-06	0.000102	CbGpPWpGaD
